Drug Profile
Research programme: recombinant protein therapeutics - Beijing Northland Biotech
Alternative Names: NL 001; NL 202Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Beijing Northland Biotech
- Class Recombinant proteins
- Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Blood coagulation factor replacements; Cell movement activators; Collagen stimulants; Factor X stimulants; Nerve growth factor stimulants; Stem cell stimulants; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia A; Myocardial infarction; Psoriasis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Haemophilia-A in China
- 28 Jul 2020 No recent reports of development identified for preclinical development in Psoriasis in China
- 28 Jan 2020 No recent reports of development identified for preclinical development in Myocardial-infarction in China